71 related articles for article (PubMed ID: 6334133)
1. Interleukin-2 administered in vivo induces the growth and augments the function of cultured T cells in vivo.
Cheever MA; Thompson JA; Kern DE; Greenberg PD
J Biol Response Mod; 1984 Oct; 3(5):462-7. PubMed ID: 6334133
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo.
Cheever MA; Greenberg PD; Irle C; Thompson JA; Urdal DL; Mochizuki DY; Henney CS; Gillis S
J Immunol; 1984 May; 132(5):2259-65. PubMed ID: 6609193
[TBL] [Abstract][Full Text] [Related]
3. Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2.
Chen W; Reese VA; Cheever MA
J Immunol; 1990 May; 144(10):3659-66. PubMed ID: 2332628
[TBL] [Abstract][Full Text] [Related]
4. Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression.
Chen W; Cheever MA
J Immunol; 1994 May; 152(10):4767-74. PubMed ID: 8176202
[TBL] [Abstract][Full Text] [Related]
5. Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implications for the use of interleukin-2.
Greenberg PD; Cheever MA
J Biol Response Mod; 1984 Oct; 3(5):455-61. PubMed ID: 6239012
[TBL] [Abstract][Full Text] [Related]
6. Potential uses of interleukin 2 in cancer therapy.
Cheever MA; Thompson JA; Peace DJ; Greenberg PD
Immunobiology; 1986 Sep; 172(3-5):365-82. PubMed ID: 3492434
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth.
Cheever MA; Thompson JA; Kern DE; Greenberg PD
J Immunol; 1985 Jun; 134(6):3895-900. PubMed ID: 3872906
[TBL] [Abstract][Full Text] [Related]
8. Potential for specific cancer therapy with immune T lymphocytes.
Cheever MA; Greenberg PD; Fefer A
J Biol Response Mod; 1984; 3(2):113-27. PubMed ID: 6233396
[TBL] [Abstract][Full Text] [Related]
9. Antigen-specific cultured T cells can mediate tumor therapy and provide long-term immunologic memory in vivo.
Cheever MA; Klarnet JP; Peace DJ; Greenberg PD
Prog Clin Biol Res; 1987; 244():49-58. PubMed ID: 3498958
[TBL] [Abstract][Full Text] [Related]
10. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
11. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.
Greenberg PD; Cheever MA
J Immunol; 1984 Dec; 133(6):3401-7. PubMed ID: 6149246
[TBL] [Abstract][Full Text] [Related]
12. Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo.
Chen W; Schweins E; Chen X; Finn OJ; Cheever MA
J Immunol; 1994 Oct; 153(8):3630-8. PubMed ID: 7930583
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific Il-4- and IL-10-secreting CD4+ lymphocytes increase in vivo susceptibility to Trypanosoma cruzi infection.
Barbosa de Oliveira LC; Curotto de Lafaille MA; Collet de Araujo Lima GM; de Almeida Abrahamsohn I
Cell Immunol; 1996 May; 170(1):41-53. PubMed ID: 8660798
[TBL] [Abstract][Full Text] [Related]
14. Experimental allergic encephalomyelitis. T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain.
Skundric DS; Huston K; Shaw M; Tse HY; Raine CS
Lab Invest; 1994 Nov; 71(5):671-9. PubMed ID: 7526038
[TBL] [Abstract][Full Text] [Related]
15. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Aug; 135(2):1488-97. PubMed ID: 3891854
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
Matsumura T; Sussman JJ; Krinock RA; Chang AE; Shu S
Cancer Res; 1994 May; 54(10):2744-50. PubMed ID: 8168105
[TBL] [Abstract][Full Text] [Related]
17. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
18. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia.
Greenberg PD
J Immunol; 1986 Mar; 136(5):1917-22. PubMed ID: 3485134
[TBL] [Abstract][Full Text] [Related]
19. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.
Cheever MA; Thompson DB; Klarnet JP; Greenberg PD
J Exp Med; 1986 May; 163(5):1100-12. PubMed ID: 3084700
[TBL] [Abstract][Full Text] [Related]
20. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression.
Voronov E; Weinstein Y; Benharroch D; Cagnano E; Ofir R; Dobkin M; White RM; Zoller M; Barak V; Segal S; Apte RN
Cancer Res; 1999 Mar; 59(5):1029-35. PubMed ID: 10070959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
